4//SEC Filing
Schranz Jennifer 4
Accession 0001104659-19-005519
CIK 0001641640other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:06 PM ET
Size
8.3 KB
Accession
0001104659-19-005519
Insider Transaction Report
Form 4
Schranz Jennifer
Chief Medical Officer
Transactions
- Award
Stock Options
2019-01-31+235,000→ 235,000 totalExp: 2029-01-31→ Ordinary Shares (235,000 underlying) - Award
Restricted Stock Units
2019-01-31+52,500→ 52,500 totalExp: 2023-01-31→ Ordinary Shares (52,500 underlying)
Footnotes (4)
- [F1]The exercise price is $1.90 per share.
- [F2]This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
- [F3]The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units.
- [F4]The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period.
Documents
Issuer
Nabriva Therapeutics plc
CIK 0001641640
Entity typeother
Related Parties
1- filerCIK 0001735382
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 4:06 PM ET
- Size
- 8.3 KB